Inhibition of oxidative stress mediated by Aβ1-42 oligomers and the rescue of the fractalkine receptor CX3CR1 have been recently considered as novel therapeutic strategies to prevent neuronal loss and cognitive decline in AD pathology. The gene discussed is CX3CR1; the disease is Alzheimer disease.